Top-line results for a Phase 2 trial of sonelokimab in moderate-to-severe HS expected around the end of June 2023 with final read-out by Q4 2023;Completion of patient enrollment and randomization for the ongoing Phase 2 trial of sonelokimab in active PsA expected in Q3 2023; Top-line results for a Phase 2 trial of sonelokimab in active PsA anticipated on schedule at the end of the year
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MLTX:
- MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update
- MoonLake Immunotherapeutics management to meet with Cantor Fitzgerald
- Cantor biopharma/biotech analysts hold analyst/industry conference call
- MoonLake Immunotherapeutics initiated with a Buy at BTIG
- MoonLake initiated with an Overweight at Cantor Fitzgerald